Skip to main content
Back
CLCGY logo

Clicks Group Limited

Data quality: 100%
Oversold
CLCGY
OTC Healthcare Medical - Pharmaceuticals
$33.51
▼ $1.18 (-3.40%)
Mkt Cap: 3.95B
Day Range
$33.38 $33.84
52-Week Range
$33.38 $44.89
Volume
898
50D / 200D Avg
$39.52 / $40.93
Prev Close
$34.69

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 1.3 0.3
P/B 0.6 2.9
ROE % 48.1 3.7
Net Margin % 6.3 3.8
Rev Growth 5Y % 7.6 10.0
D/E 1.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.00
$0.00 – $0.00
 56 B 0
FY2026 $0.00
$0.00 – $0.00
 52 B 0

Key Takeaways

Revenue grew 7.58% annually over 5 years — modest growth
ROE of 48.10% indicates high profitability
Generating 4.15B in free cash flow
P/E of 1.25 — trading at a low valuation
PEG of 0.43 suggests growth is underpriced
Cash machine — converts 131.53% of earnings into free cash flow

Growth

Revenue Growth (5Y)
7.58%
Revenue (1Y)10.07%
Earnings (1Y)11.23%
FCF Growth (3Y)32.06%

Quality

Return on Equity
48.10%
ROIC25.22%
Net Margin6.31%
Op. Margin9.12%

Safety

Debt / Equity
0.98
Current Ratio1.11
Interest Coverage12.85

Valuation

P/E Ratio
1.25
P/B Ratio0.58
EV/EBITDA1.63
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.07% Revenue Growth (3Y) 9.62%
Earnings Growth (1Y) 11.23% Earnings Growth (3Y) 11.52%
Revenue Growth (5Y) 7.58% Earnings Growth (5Y) 14.47%
Profitability
Revenue (TTM) 50.01B Net Income (TTM) 3.16B
ROE 48.10% ROA 14.01%
Gross Margin 25.49% Operating Margin 9.12%
Net Margin 6.31% Free Cash Flow (TTM) 4.15B
ROIC 25.22% FCF Growth (3Y) 32.06%
Safety
Debt / Equity 0.98 Current Ratio 1.11
Interest Coverage 12.85 Dividend Yield 0.02%
Valuation
P/E Ratio 1.25 P/B Ratio 0.58
P/S Ratio 0.08 PEG Ratio 0.43
EV/EBITDA 1.63 Dividend Yield 0.02%
Market Cap 3.95B Enterprise Value 7.44B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 50.01B 45.44B 41.62B 39.59B 37.34B
Net Income 3.16B 2.84B 2.54B 2.64B 1.84B
EPS (Diluted) 39.32 23.84 20.84 21.60 14.88
Gross Profit 12.75B 10.63B 9.31B 8.43B 7.27B
Operating Income 4.56B 4.17B 3.62B 3.65B 2.90B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22.52B 20.82B 19.03B 17.86B 17.17B
Total Liabilities 15.69B 14.53B 13.07B 12.17B 12.37B
Shareholders' Equity 6.84B 6.29B 5.96B 5.70B 4.81B
Total Debt 6.73B 3.79B 3.24B 3.10B 2.92B
Cash & Equivalents 3.25B 2.70B 2.46B 2.01B 2.21B
Current Assets 14.20B 12.89B 11.83B 11.37B 11.24B
Current Liabilities 12.77B 11.83B 10.80B 9.93B 10.20B

Strategy Scores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#180 of 1052
63
Growth Price/Sales Ratio Focus (Ken Fisher)
#546 of 618
11
Custom Contrarian Investing (David Dreman)
#123 of 670
52

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Contrarian Investing (David Dreman)
Mar 24, 2026